

Nottinghamshire Area Prescribing Committee

May 2019 Bulletin



www.nottsapc.nhs.uk www.nottinghamshireformulary.nhs.uk MACCG.NottsAPC@nhs.net

May 2019 APC Decisions

Medicine	Status	Indication	Other Information	
Noqdirna® (Desmopressin)	Amber 2	Nocturia	 Women: 25 microgram daily, one hour before bedtime. Men: 50 microgram daily, one hour before bedtime Administered sublingually without water 	
Softacort® (Hydrocortisone sodium phosphate 0.3% PF single use eye drops)	Amber 2	Ocular surface inflammation	 Ocular surface inflammation requiring steroids Where intraocular penetration is not desirable and for which Prednisolone PF UD would otherwise be used 	
Ertugliflozin	Amber 3	Diabetes	 Monotherapy or with metformin for treating type 2 diabetes (NICE TA 572) 	
Jorveza® (Budesonide 1mg orodispersible tabs)	Deferred - RED recommended	Eosinophilic oesophagitis	 Deferred to trust DTCs for classification Classification to be reviewed following publication of NICE TA due in October. 	

News from the APC - Ratified at the meeting:

Framework for Managing Medicines across the Nottinghamshire Health Community (Update)

APC Annual Report 2018-19

Type 2 Diabetes Guideline (Interim minor update)

<u>Azathioprine Shared Care Protocol</u> - (Updated to ensure monitoring schedule is consistent across all indications)

REMINDER - The Antimicrobial guidelines <u>have moved</u> and been <u>updated</u>. The following link can be saved on your device for quick access -

https://www.nottsapc.nhs.uk/guidelines-formularies/antimicrobial-guidelines/

Printed copies become out of date quickly and may lead to incorrect prescribing

QUICK TIPS

The Allergic Rhinitis Primary Care Pathway for adults allows prescribers to work through a variety of treatment options prior to referral to secondary care. Step 4 includes Dymista (Fluticasone Propionate/Azelastine nasal spray) which is Amber 3 and can be prescribed in primary care according to the pathway.

First line treatment of non-severe suspected <u>C. difficile</u> associated diarrhoea is oral vancomycin. Community pharmacists are likely to need to order this medication in which may take up to 48 hours. It is advised to provide a prescription for 3 days worth of metronidazole in the interim. The CCGs will be looking to commission a community Pharmacy scheme to ensure supply is available in the future.

The <u>Guidelines for Medicines used during Foreign Travel</u> has been published on the <u>Shared Medicines Management website</u>. This provides guidance on the provision of travel vaccinations, malaria prophylaxis and associated travel medications. It also details guidance on those patients living abroad for more than 3 months of the year.

Horizon Scanning, Formulary amendments and traffic light changes

Horizon scanning - GREY classification assigned until formal submission is requested

- ⇒ Sodium zirconium cyclosilicate for hyperkalaemia
- ⇒ Prasterone 6.5mg pessary for vulval and vaginal atrophy

Formulary amendments and traffic light changes

- ⇒ SyreniRing contraceptive vaginal ring added as GREEN
- ⇒ Asacol suppositories removed as discontinued
- ⇒ Humalog Junior Kwikpen 100units/ml Added as AMBER 2
- ⇒ Ferrous sulphate added as **GREEN**, more cost effective than fumarate.
- Mexiletine (Namuscla 167mg) for myotonia licensed product launched. AMBER 2 classification for ventricular arrhythmias remains. GREY for all other indication.

Current work in development

- ⇒ Osteoporosis Guideline and bisphosphonate information sheet
- ⇒ Out of area prescribing request guidance
- ⇒ Anticoagulants in AF and DOACs for DVT/PE guide
- ⇒ Urticaria primary care pathway
- ⇒ Male LUTS guideline
- ⇒ Naltrexone prescribing information sheet
- ⇒ Dementia short guide
- ⇒ Chronic constipation pathway
- ⇒ End of Life Guidelines
- ⇒ ADHD shared care protocols
- ⇒ Combination inhaler reference guide
- ⇒ Orlistat patient agreement
- ⇒ Alcohol primary care guide

Upcoming NICE publications

TITLE	GUIDELINE/TA	EXPECTED DATE			
Hypertension in Adults	Guideline	August 2019			
Ertugliflozin in a triple therapy regimen for treating type 2 diabetes	ТА	June 2019			
Osteoarthritis: care and management	Guideline	May 2019			
Dapagliflozin, in combination with insulin, for treating type 1 diabetes	TA	August 2019			
Hypertension in pregnancy	Guideline	June 2019			
Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease	TA	August 2019			
Chronic obstructive pulmonary disease in over 16s: diagnosis and management	Guideline	July 2019			